Biosimilars are becoming increasingly important in the European Union’s biopharmaceutical landscape due to the increased growth of biologicals as key therapies and the financial pressure this puts on healthcare budgets.
Both generic and innovator companies are players in the biosimilars market, and such drug products can present potential savings for payers. In certain cases biosimilars have gained over 90% of the market share within one to two years of launch1 . This article examines the process for the approval of biosimilars in the EU; the way in which safety and risk management is conducted; and market access issues.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
The approval process Biological products are large molecules that are typically derived from living cells. They are characterised as being highly sensitive to manufacturing and handling processes, which makes them more challenging to produce (and copy) than small molecules. A biosimilar product is defined as a biological medicinal product that is similar to a reference biological product, but that does not meet the conditions in the definition of a generic medicinal product owing, in particular, to differences in raw materials or manufacturing processes.
The approval of biosimilar products has been facilitated since the introduction of a specific provision in the Medicinal Code2 . So far, twenty biosimilar products have been approved via the centralised approval process relating to eight different reference biological products – the most recent being Benepali (etanercept)3 .
The legal basis for the approval of biosimilars, Article 10.4 of the Medicinal Code, sets out the definition of a similar biological product and clarifies that an application for a marketing authorisation for a biosimilar must include the results of appropriate preclinical tests or clinical trials demonstrating similarity with the reference biological product. The goal is to exclude any relevant differences between the biosimilar and the reference product and to confirm comparable clinical performance. This contrasts with the requirements for generic medicinal products, where the applicant need only provide the results of bioavailability studies demonstrating bioequivalence with the reference medicinal product.
The type and quantity of supplementary data to be provided is set out in Annex I of the Medicinal Code and in detailed biosimilar guidelines issued by the European Medicines Agency (EMA)4 . These guidelines consist of: (a) overarching guidelines on similar biological medicinal products, non-clinical and clinical issues and quality issues; (b) product-specific guidelines such as those that include recombinant follicle-stimulating hormone, interferon beta and recombinant erythropoietins; and (c) other relevant guidelines.
From the date of submission of the marketing authorisation application, the approval process for a biosimilar product generally takes between one and one and a half years. The average cost for developing a biosimilar is estimated to range from $40 million to $375 million – this compares with the $4 million price for developing a generic medicinal product.
The first biosimilar product to be approved in the EU was Sandoz’s Omnitrope, containing the growth hormone somatropin, which was approved on the 12th of April 2006. Interestingly, Sandoz had tried to obtain a marketing authorisation for Omnitrope sometime before Medicinal Code 2004/27/EU came into effect using the process for bibliographic applications based on well-established medicinal use, but this approach was rejected by the European Commission.
Safety and risk management
Pharmacovigilance
Due to the complexities in the manufacturing and production of biosimilars, it has been accepted that for the purposes of pharmacovigilance monitoring it is important to identify the product, manufacturer and batch number in adverse event reports.
Article 102(e) of the Medicinal Code requires Member States to ensure that measures are taken to clearly identify any biological medicine which is the subject of an adverse event report, with due regard to name and batch number.
It is interesting to note that the position of the EMA towards the monitoring of the safety profile of biosimilars appears to have evolved in recent years. Indeed, until recently the EMA’s position was rather cautious, and its overarching Guideline on Similar Biological Medicinal Products published in 2005 stated that “it should be recognised that, by definition, similar biological medicinal products are not generic medical products, since it could be expected that there may be subtle differences between similar biological medicinal products from different manufacturers or compared with reference products, which may not be fully apparent until greater experience in their use has been established. Therefore, in order to support pharmacovigilance monitoring, the specific medicinal product given to the patient should be clearly identified.” However, the 2014 version of this Guideline only states that: “in order to support pharmacovigilance monitoring … all appropriate measures should be taken to clearly identify any biological medicinal product which is the subject of a suspected adverse reaction report, with due regard to its brand name and batch number”.
In the United Kingdom the Medicines and Healthcare products Regulatory Agency (MHRA) has highlighted in Drug Safety Updates that, in order for them to perform product/brand-specific pharmacovigilance, the brand name (or product licence number and manufacturer) and the specific batch-number should be included on reports for suspected adverse drug reactions for biological medicines5 .
Naming of biosimilars
There are ongoing debates regarding the naming of biosimilars. The EU’s current position is that biosimilars share the same common name as the reference product. Interestingly, in June 2015 the World Health Organization issued a consultation paper proposing the introduction of a biological qualifier (BQ) for all biological products consisting of a four letter sequence that would identity an active substance as being produced by the same corporate entity. The consultation closed in November 2015. However, in the EU the practice of providing brand names within adverse event reports appears to have worked well: a survey of 13,790 biologic entries in the EudraVigilance system showed a >96% ability to track the biosimilar6 .
Risk management
All biosimilars bear a ‘black triangle’, which indicates that the product is subject to additional monitoring. A European list of medicines under additional monitoring is published every month by the Pharmacovigilance Risk Assessment Committee (PRAC). A medicine usually remains under additional monitoring for five years or until the PRAC is satisfied that it can be removed from the list.
Every biosimilar authorised by the European Medicines Agency will have a risk management plan in place, details of which will be in the European Public Assessment Report. The types of risk management activities that a biosimilar manufacturer may be required to undertake and be responsible for can include the provision of additional information, alert cards or educational materials/websites to patients and/or physicians.
Patient registries are also common risk management activities for biological medicines and biosimilars may need to be incorporated into existing or new registries. There may need to be engagement and co-operation between healthcare professionals, patients and different manufacturers in relation to the management of these registries.
The average cost for developing a biosimilar is estimated to range from $40 million to $375 million – this compares with the $4 million price for developing a generic medicinal product
Prescribing and substitution Unlike with generic versions of small molecules (which rapidly replace the branded product once they are approved and, where relevant, awarded tenders), the uptake of biosimilar products has been highly diverse across Member States and therapy areas. This is because although the authorisation of the biosimilar products has been through the centralised approval procedure, control over reimbursement, prescription and pharmacy substitution remains at a national member state level. It is generally accepted that the automatic substitution of biosimilar products at pharmacy level is not appropriate due to the nature of the products.
In the UK automatic pharmacy substitution (being the practice of dispensing one medicine instead of another equivalent and interchangeable medicine at the pharmacy level without consulting the prescriber) is not permitted in relation to products that have been prescribed by brand name. International non-proprietary name (INN) prescribing is the established practice within the National Health Service (NHS) for most other products, so the MHRA has issued guidance stating that it is good practice to prescribe biological products by brand name to ensure that automatic substitution does not occur, in its Drug Safety Update for Biosimilar Products dated February 2008. In addition, NHS England Guidance issued in September 20157 clarifies that, whilst prescribers are always able to switch treatments for a given patient provided it is safe to do so and there are appropriate monitoring arrangements in place, automatic substitution is not appropriate for biosimilar products and the main way to ensure that this does not happen is through brand prescribing.
Prescribing practices are ultimately determined by the prescribing physician, however, in practice physicians will need to take into account national (or local) prescribing guidance from regulators, payers, or professional/academic associations which will influence their prescribing choice.
Prescribing and substitution practices do vary among the Member States, but in most cases either law or guidelines prohibit the automatic substitution of biosimilars. The notable exception is in France where, by law, pharmacists are allowed to substitute a biosimilar for the originator’s biological product provided that the treatment is the initiation of a new course of treatment and the physician has not indicated that the prescription is ‘non-substitutable’.
Market access
The uptake of biosimilars has experienced variations at the molecule level, therapy area and country level, for several different reasons.
The payer environment and procurement model has in some cases been a key factor, and can set the tone for the other stakeholders involved in the substitution decision. For example, if a tender system is in place and a single national tender is awarded to a biosimilar, then the biosimilar may obtain almost the entire market share for that product. On some occassions even a minor cost saving will be enough to win a tender. As an example, the uptake of biosimilar infliximab in certain Nordic countries between 2014 and 2016 rose to over 90% of the market share, by winning tenders purely based on a price discount. However, there is not always a strong correlation between price differential and uptake.
HTA bodies and payers are starting to implement strategies to support the effective uptake of biosimilars, from a practical and clinical perspective. For example, in the UK in January 2015 the health technology appraisal body, the National Institute for Health and Care Excellence (NICE), published a position statement on evaluating biosimilar medicines, clarifying that where biosimilars are notified to the NICE topic selection process for referral to the technology appraisal programme, they will usually be considered in the context of a multiple technology appraisal, in parallel with their reference products in the indication under consideration.
In the case of the biosimilar infliximab, NICE produced an ‘adoption resource’ to help manage the introduction of biosimilars into care pathways safely and effectively, which included findings and shared experiences from NHS organisations. Some examples of these findings were the need to consult all stakeholders (including patients) to ensure confidence in the use of the biosimilar; the provision of information regarding the approval process by the EMA; identifying cost savings; seeking approval at the local formulary committee; identifying baseline data to be collected during and after the introduction of the biosimilar; and submitting data to national audits and registries.
Another example is the effort to collect real-world data regarding switching patients to biosimilars in Norway. The NOR-SWITCH study is being run and supported financially by the Norwegian government to evaluate the maintenance of efficacy and adverse event monitoring following patient switch from reference to biosimilar infliximab. The study will run over 12 months and the results are expected to be available at the end of 2016.
Clinical innovation factors such as second-generation products, which have recognised and/or added value, can also impact biosimilar uptake, but may not be decisive in the face of cost savings.
The uptake would also depend on whether the biosimilar qualifies as a ‘biobetter’, namely whether the biosimilar is an improved version of the reference biological product, by having an improved pharmacodynamic or pharmacokinetic profile resulting in enhanced safety, efficacy or manufacturing characteristics, different forms of delivery or even lower dosing. There are appealing commercial advantages to biobetters as opposed to biosimilars. Recent cases illustrate that companies are prepared to concentrate research and development resources into developing biobetters; see, for example, the development and launch of Neulasta (pegfilgrastim) and Aranesp (darbepoetin alfa)8.
The future of biosimilars
What does the future hold for biosimilars? It is likely that in the future biosimilars will become more readily substituted at a prescribing (rather than pharmacy) level, as confidence grows in their use and strategies for monitoring before and after switching become more well used. It will remain important to track and record which product a patient receives, for safety reasons, and for biosimilars manufacturers to implement robust risk management activities. As pressure on healthcare budgets increases, cost saving is likely to become a key driver for the use of biosimilars where it is clinically appropriate to do so.
About the author
Hilary Jones is a Senior Associate in the Bristows IP Regulatory team, specialising in all aspects of EU and UK law in the biopharmaceutical and medical devices sectors. Hilary previously worked at Pfizer and at Gilead Sciences, supporting the global business units, bringing a strong business approach to her legal advice.
Hi Doug, we’re glad you enjoyed it. If you click here, you’ll be able to view the Digital version of the magazine which has all the references in footnotes at the bottom of each article. Hope that helps!
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
Great article.
Please could you supply the references?
Thanks – Doug
Hi Doug, we’re glad you enjoyed it. If you click here, you’ll be able to view the Digital version of the magazine which has all the references in footnotes at the bottom of each article. Hope that helps!